Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-22 23:58 CEST (UTC+2h)

Full replicate designed study for Europe [RSABE / ABEL]

posted by balakotu - India, 2018-03-31 11:59  - Posting: # 18625
Views: 922

Dear Members,
I need some suggestion regarding full replicate study statistical data analysis for Europe scope. Study conducted in four period full replicate design. Majority of the subjects completed all four period of the study and some subjects completed at least two periods with one test and one reference treatments.
The subjects with at lease two reference treatments included in calculation of ISCVR.
The study showing more than 30% ISCVR. The study eligible for scaled average bio equivalence approach. (widening criteria for Cmax). The subjects who completed all four periods will be included in PK and Stats. Here my question is whether to include the subjects who completed at least one test and one reference for bio-equivalence calculation?

Thanks and regards

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,190 registered users;
online 17 (0 registered, 17 guests [including 13 identified bots]).

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed